F3 and neoplasm: From SOM to EOT, e.g. during tumor progression on single bevacizumab treatment, weak evidence was observed for increase in the level of five proteins (TIMP-4, MMP-8, EGF, Amphiregulin, and Tissue factor/Coagulation factor III), whereas a decrease was seen in only one protein (CD26).